Patents
Literature
32 results about "Cholinergic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cholinergic agents are compounds which mimic the action of acetylcholine and/or butyrylcholine. In general, the word choline refers to the various quaternary ammonium salts containing the N,N,N-trimethylethanolammonium cation. Found in most animal tissues, choline is a primary component of the neurotransmitter acetylcholine and functions with inositol as a basic constituent of lecithin. Choline also prevents fat deposits in the liver and facilitates the movement of fats into cells. The richest nutritional sources of choline are liver, kidney, brain, wheat germ, brewer's yeast, and egg yolk. Neurologically, cholinergic is the abbreviated term referring to choline (the suffix -ergic means stimulating). The parasympathetic nervous system, which uses acetylcholine almost exclusively to send its messages, is said to be almost entirely cholinergic. Neuromuscular junctions, preganglionic neurons of the sympathetic nervous system, the basal forebrain, and brain stem complexes are also cholinergic. In addition, the receptor for the merocrine sweat glands are also cholinergic, since acetylcholine is released from postganglionic sympathetic neurons.
Protein powder for assisting in improving Alzheimer's disease and preparation method thereof
The invention belongs to the technical field of food nutrition and health, and particularly discloses protein powder for assisting in improving Alzheimer's disease and a preparation method of the protein powder according to the concept of dietary therapy in China, and the protein powder is prepared from the following components in percentage by weight: 35-45% of egg white protein peptide powder and 55-65% of core function compound powder. According to the invention, egg white protein peptide is used as a high-quality matrix, and nine specific medicinal materials including hippocampus, egg yolk phospholipid, egg membrane peptide, walnut, fructus alpiniae oxyphyllae, gastrodia elata, mulberry, sargassum fusiforme, wolfberry, ginkgo leaf, fructus evodiae and dandelion are cooperatively compatible; aiming at seven core pathological links of Alzheimer's disease, such as A beta deposition, Tauopathy, neuroinflammation, oxidative stress, cholinergic deficiency, neurodystrophy and cerebral circulation disorder, a multi-target synergistic effect network is constructed, comprehensive neuroprotection is realized, and tests prove that the space learning and memory ability and the autonomous activity ability can be effectively improved.
Owner:HEFEI UNIV OF TECH
Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors
The present application relates to a kind of thieno [2, 3-c] pyridazine derivatives, and its isotope form, stereoisomer, tautomer, cis-trans isomer, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, hydrate, prodrug and polymorph, these compounds can be used as cholinergic M4 receptor positive allosteric modulator, it has good application prospect in preparation for preventing and / or treating the drug for the disease related to abnormal muscarinic acetylcholine receptor.
![Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors](https://images-eureka.patsnap.com/patent_img/02eeb2b6-d9ae-4370-91ad-3465dbea0096/SMS_1.png "Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors")
![Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors](https://images-eureka.patsnap.com/patent_img/02eeb2b6-d9ae-4370-91ad-3465dbea0096/SMS_3.png "Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors")
![Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors](https://images-eureka.patsnap.com/patent_img/02eeb2b6-d9ae-4370-91ad-3465dbea0096/SMS_4.png "Thieno[2,3-c]pyridazine derivatives as positive allosteric modulators of cholinergic m4 receptors")
Owner:南京雷正医药科技有限公司
Benzoazepine compounds for treating brain organic lesions as well as preparation method and application of benzoazepine compounds
The invention belongs to the technical field of medicinal chemistry, and relates to a benzazepine compound or pharmaceutically acceptable salt thereof as well as a preparation method and application of the benzazepine compound, in particular to a compound with a structural general formula as shown in a formula (I). The benzoazepine compound disclosed by the invention has a remarkable curative effect on treating brain organic lesion diseases, including vascular lesion and degenerative lesion, especially vascular dementia, Alzheimer's disease and cholinergic deficiency related diseases. Formula (I).
Owner:SHENYANG PHARMA UNIV
Epileptic seizure prevention or treatment via heart rate clamping
We report a method of treating an epileptic seizure in a patient, comprising: detecting said epileptic seizure, based on body data from said patient; and reducing a flow of blood to a brain of said patient in response to said detected seizure; wherein said reducing is effected by: increasing the parasympathetic input to said patient's heart, such as by electrically stimulating a parasympathetic nervous structure, applying cooling energy to a sympathetic nervous structure, or administering a cholinergic or a sympatho-blocking agent to said patient. We also report a medical device system configured to implement the method. We also report a non-transitory computer readable program storage unit encoded with instructions that, when executed by a computer, perform the method.
Owner:FLINT HILLS SCIENTIFIC LLC
A nanoliposome suspension for soft fogging and its preparation method
A nanoliposome suspension for soft aerosol spray and its preparation method are disclosed. The active ingredient of the nanoliposome suspension is selected from the following combinations: inhaled glucocorticoids, long / short-acting β2 receptor agonists and long / short-acting anticholinergic drugs (LAMA / SAMA), inhaled glucocorticoids, long / short-acting β2 receptor agonists and long / short-acting anticholinergic drugs, inhaled glucocorticoids and long / short-acting β2 receptor agonists, inhaled glucocorticoids and long / short-acting anticholinergic drugs; the active ingredient is encapsulated in nanoliposomes, which are prepared using cholesterol and phospholipids.
Owner:TIANJIN TIANYAO PHARM CO LTD
Use of a lysophosphatidylcholine in promoting early development of a reconstituted embryo and method
This invention provides an application and method of lysophosphatidylcholine (LPC) in promoting early development of reconstructed embryos, belonging to the field of embryo engineering technology. The invention first prepares reconstructed embryos, then adds lysophosphatidylcholine to the culture system for culturing. Lysophosphatidylcholine effectively promotes early development of the reconstructed embryos; at an optimal concentration of 5 μM, the blastocyst development rate increases to 24.56%, providing a novel and operable biochemical intervention target to solve the problem of low reconstructed embryo culture efficiency. This invention not only fills the gap in our understanding of the mechanism of action of LPC in this field, but also achieves controllability and reproducibility of the technical solution through precise definition of the optimal concentration. It provides key parameters for establishing standardized culture procedures and provides a more solid foundation for downstream applications such as developmental biology research and disease model construction that rely on high-quality reconstructed embryos, significantly accelerating the process of related scientific discovery and application development.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI
Lactobacillus gasseri strain a21120 with antioxidant, anti-inflammatory and anti-tumor functions, probiotic agent and application thereof
The application provides a lactobacillus gasseri strain A21120 with antioxidant, anti-inflammatory and antitumor functions, and a probiotic agent and application thereof, and belongs to the technical field of functional microorganisms. The strain A21120 is obtained by screening from intestinal feces of a centenarian healthy old person, and is identified by morphology and molecules and belongs to lactobacillus gasseri. The strain has good resistance to gastrointestinal fluid and bovine choline capacity, and has the potential to colonize the intestinal tract. The lactobacillus gasseri strain A21120 provided by the application has bacteriostatic, anti-inflammatory, antioxidant and antitumor activities, and provides a new way for the treatment of clinical related diseases, the development of drugs and the preparation of in vitro preparations or daily necessities.
Owner:GUANGXI ACAD OF SCI +1
Anticholinergic agents
Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M3 antagonists, which can be used for treating a variety of disorders, conditions or diseases such as hyperhidrosis.
Owner:REZUBIO PHARM CO LTD
Composition for preventing, alleviating or treating alzheimer's disease, comprising gongjindan composition as active ingredient
PCT designated stageWO2025254245A1Nervous disorderAnthropod material medical ingredientsNeurotrophic factorsAntiinflammatory Effect
The present invention relates to a composition for preventing, alleviating or treating Alzheimer's disease, comprising a Gongjindan composition as an active ingredient. The Gongjindan composition enhances memory or cognitive function, alleviates cholinergic dysfunction, strengthens neurotrophic factors, and has antioxidant and anti-inflammatory effects.
Owner:PARK JONG KWANG +1
Use of a triacetyl andrographolide and its composition in the preparation of a drug for relaxing airway smooth muscle
The application discloses application of triacetylandrographolide and a composition thereof in preparation of a medicine for relaxing airway smooth muscle, and belongs to the technical field of medicines. In view of the problems of obvious side effects and narrow treatment window of existing medicines, the application finds that triacetylandrographolide (3, 14, 19-Triacetylandrographolide, TAA) and the composition thereof have tracheal relaxation activity, and the triacetylandrographolide and the composition thereof play a relaxation role through non-competitive antagonism of a downstream signal path of a cholinergic receptor. The new mechanism provides a new idea for developing a new bronchial dilator for overcoming drug resistance of existing medicines. The TAA after preparation optimization can be used for treating or preventing airway obstructive diseases such as asthma, chronic obstructive pulmonary disease, bronchitis and acute lung injury.
Owner:HENAN UNIVERSITY
Nitrogen-containing heterocyclic compound
PendingUS20260092052A1Nervous disorderOrganic chemistryDementia with Lewy bodiesNitrogenous heterocyclic compound
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof.wherein each symbol is as described in the specification, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD
Galantamine analog, and preparation method therefor and use thereof
The present invention relates to a galantamine analog having a cholinesterase inhibitory activity, and a preparation method therefor and the use thereof. The galantamine analog has a general structural formula as shown in formula (IA), (IB) or (IC). In formula (IA), R1 is selected from hydrogen, o-fluoro, m-fluoro, p-fluoro, 2,4-difluoro, m-trifluoromethyl, p-methyl, 3,5-dimethoxy, p-chloro, p-nitro, p-cyano or p-trifluoromethoxy. In formula (IB), R2 is selected from phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, o-methylphenyl, p-methylphenyl, p-methoxyphenyl, indole, p-cyanophenyl, p-trifluoromethylphenyl, p-trifluoromethoxyphenyl, p-nitrophenyl or naphthalene ring. In formula (IC), R3 is selected from hydrogen, o-fluoro, m-fluoro, p-fluoro, m-chloro, p-chloro, p-methyl, o-methoxy, m-methoxy or p-methoxy. The galantamine analog of the present invention has a cholinesterase inhibitory activity superior to that of galantamine, and is expected to be used for treating diseases associated with cholinergic dysfunction.
Owner:SHENYANG PHARMA UNIV
Galantamine analogs, processes for their preparation and use thereof
This invention relates to a galantamine analogue with cholinesterase-inhibiting activity, its preparation method, and its application. The general structural formula is shown in formula (IA), (IB), or (IC). In formula (IA), R1 is selected from hydrogen, o-fluorine, m-fluorine, p-fluorine, 2,4-difluoro, m-trifluoromethyl, p-methyl, 3,5-dimethoxy, p-chloro, p-nitro, p-cyano, or p-trifluoromethoxy. In formula (IB), R2 is selected from phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, o-methylphenyl, p-methylphenyl, p-methoxyphenyl, indole, p-cyanophenyl, p-trifluoromethylphenyl, p-trifluoromethoxyphenyl, p-nitrophenyl, or a naphthalene ring. In formula (IC), R3 is selected from hydrogen, o-fluorine, m-fluorine, p-fluorine, m-chloro, p-chloro, p-methyl, o-methoxy, m-methoxy, or p-methoxy. The galantamine analogue of this invention exhibits superior inhibitory activity against cholinesterase compared to galantamine, and holds promise for the treatment of cholinergic dysfunction-related diseases.
Owner:SHENYANG PHARMA UNIV
Dry powder composition for relaxing airway, dry powder inhalation preparation and preparation method thereof
The invention provides a dry powder composition for relaxing an airway, a dry powder inhalation preparation and a preparation method thereof, and relates to the technical field of medicines, the dry powder composition comprises a carrier and a micronized drug active ingredient dispersed in the carrier, and the mass ratio of the micronized drug active ingredient to the carrier is 1: (11-21); the carrier comprises a coarse powder carrier and a micronized fine powder carrier; the pharmaceutical active component is composed of JKN2304 and glucocorticoid, a JKN2304-glucocorticoid duplex dry powder composition with inhaled glucocorticoid (ICS) and a beta2 receptor agonist effect and a cholinergic M receptor antagonist effect is constructed, the effects of relaxing the airway and inhibiting inflammation are achieved at the same time, the problem that a single powder inhalation is single in effect is solved, and the pharmaceutical composition is suitable for clinical application. The possibility of drug interaction is reduced. The dosage of fine particles is increased; the coarse powder carrier improves the fluidity and the total delivery amount, and a dispersion-delivery synergistic mechanism is formed.
Owner:JOINCARE HAIBIN PHARM CO LTD
Formulation for soft anticholinergic analogs
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. 20 24 22 77 14 29 O ct 2 02 4 A B S T R A C T 2 0 2 4 2 2 7 7 1 4 2 9 O c t 2 0 2 4
Owner:BODOR LABORATORIES INC
Nasal Spray Device for Cholinergic Drug Delivery in Alzheimer’s Disease
Owner:MS MAMTA KUMARI +9
Composition modulating botulinum neurotoxin effect
The present invention relates to a method for modulating the effect of a botulinum neurotoxin composition, that is accelerating the onset of action and / or extending the duration of action and / or enhancing the intensity of action of a botulinum neurotoxin composition, comprising adding at least one postsynaptic inhibitor of cholinergic neuronal transmission to the botulinum neurotoxin composition. The invention also relates to compositions comprising at least one postsynaptic inhibitor of cholinergic neuronal transmission and a botulinum neurotoxin, and their uses for treating aesthetic or therapeutic conditions.
Owner:ALLERGAN PHARMACEUTICALS IRELAND UNLIMITED CO
Cyperus esculentus polypeptide as well as preparation method and application thereof
The invention relates to the technical field of extraction and application of bioactive peptides, in particular to a cyperus esculentus polypeptide and a preparation method and application thereof.The cyperus esculentus polypeptide is obtained by taking cyperus esculentus meal as a raw material, extracting through an alkali-solution and acid-precipitation treatment and enzymolysis method and separating through an ultrafiltration membrane with the molecular weight cutoff of 3 kDa; the cyperus esculentus polypeptide contains peptide fragments as shown in SEQ ID NO. 1 to SEQ ID NO. 30. The cyperus esculentus polypeptide prepared by the preparation method disclosed by the invention is beneficial to improving a cognitive function, improving memory and learning ability, relieving oxidative stress of brain tissues, recovering a cholinergic system function and inhibiting neuroinflammation, and also can be used for remodeling an intestinal flora structure and increasing abundance of beneficial bacteria.
Owner:NORTHWEST A & F UNIV +1
Paraxanthine-based bioactive composition and method of use thereof
The disclosed compositions and methods relate to compositions for human consumption comprising paraxanthine and a cholinergic agent and / or theanine. The disclosed compositions are useful for promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
Owner:PX ING LLC
Cholinergic immunotherapy for treatment of liver cancer
It has been found that the presence of cholinergic T cells is important for an effective immune response against hepatocellular carcinoma (HCC). These results demonstrate a new aspect of modulating cancer immune surveillance by immune cell-derived neurotransmitters and elucidate their effect in supporting cells to produce anti-tumor responses. Methods of treating HCC in a subject in need thereof are disclosed. Generally, the methods involve treating a subject with a therapy effective to increase acetylcholine levels in T cells. Also disclosed are methods in which a subject is treated with an anti-PD-1 immunotherapy when the determined cholinergic T cell level in the subject is high, or a subject is prevented from being treated with an anti-PD-1 immunotherapy when the determined cholinergic T cell level in the subject is low.
Owner:THE UNIVERSITY OF HONG KONG +2
Neural stem cell for treating Alzheimer's disease and preparation process thereof
PendingCN121538167ACell dissociation methodsNervous disorderDirected differentiationMedicinal chemistry
The invention relates to the technical field of biological medicine, in particular to a neural stem cell for treating Alzheimer's disease and a preparation process, according to the preparation process, separation process optimization, amplification system strengthening and directional differentiation means innovation are performed, and the prepared neural stem cell has the characteristics of high purity, high dryness and high cholinergic differentiation efficiency; the neural stem cells prepared by the process are expected to provide a reliable seed cell source for AD cell therapy.
Owner:GUANGDONG CELL BIOTECHNOLOGY CO LTD
Anticholinergic agents and muscarinic agonists for the treatment of demodex related conditions
Provided herein are methods of treating a skin affliction, an ophthalmological affliction, or an autoimmune disease comprising administering or applying to an individual having the skin affliction an active agent in a dosage sufficient to inactivate demodex brevis and / or demodex folliculorum mites from hair follicles and / or skin of the individual, resulting in amelioration or cessation of the manifestations of allergic and / or vasomotor responses to the mites that cause symptoms and signs of the affliction or disease in the individual. Also provided herein are pharmaceutical formulations suitable for any of the methods.
Owner:ATTILLAPS HOLDINGS INC
Compositions and methods for delivery of ophthalmological actives
The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs).In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof, a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject.The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.
Owner:ADS THERAPEUTICS LLC
Preparation of a hydrophobic compound high-encapsulation protein carrier and use thereof
This invention discloses the preparation and application of a hydrophobic compound high-encapsulation protein carrier, belonging to the field of bionanomaterials and food functional factor delivery technology. This invention provides a hydrophobic lumen-modified ferritin mutant rXHF, obtained by mutating polar residues at positions 68, 76, 141, and 148 on the lumen surface of human heavy chain ferritin rHuHF to tryptophan. Using this mutant as a carrier, lycopene is compounded with lycopene at a molar ratio of 1:200 to prepare the lycopene nanodelivery system rXHF-LYC. This system has a lycopene encapsulation efficiency of 17.8% and a DPPH clearance rate of 30%. Through transferrin receptor-mediated endocytosis, it crosses the blood-brain barrier, delivering lycopene to the hippocampus, inhibiting oxidative stress and neuroinflammation, restoring cholinergic function, and improving age-related cognitive impairment. This invention provides a new carrier for brain-targeted delivery of hydrophobic functional factors and offers a new strategy for the intervention of age-related neurodegenerative diseases.
Owner:DALIAN POLYTECHNIC UNIVERSITY
Methods and compositions for soft anticholinergic esters
Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.
Owner:BODOR LABORATORIES INC
Methods and compositions for the prevention and treatment of ischemia reperfusion injury and infection
ActiveUS12569498B2Cardiovascular disorderHeterocyclic compound active ingredientsAgonistIschemic reperfusion injury
Disclosed herein are compositions for treating a subject with ischemia reperfusion injury or at risk of developing ischemia reperfusion injury, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. Also disclosed are methods and compositions for treating a subject with sepsis or at risk of developing an infection or sepsis, the method comprising administering to the subject an agonist of nicotinic cholinergic receptor α7nAchR. In one embodiment, the agonist of nicotinic cholinergic receptor α7nAchR is varenicline.
Owner:CHILDRENS NAT MEDICAL CENT
Galantamine analogs, processes for their preparation and use thereof
This invention relates to a galantamine analogue with cholinesterase-inhibiting activity, its preparation method, and its application. The general structural formula is shown in formula (IA), (IB), or (IC). In formula (IA), R1 is selected from hydrogen, o-fluorine, m-fluorine, p-fluorine, 2,4-difluoro, m-trifluoromethyl, p-methyl, 3,5-dimethoxy, p-chloro, p-nitro, p-cyano, or p-trifluoromethoxy. In formula (IB), R2 is selected from phenyl, o-fluorine, m-fluorine, p-fluorine, 2,4-difluorophenyl, 3,5-difluorophenyl, o-methylphenyl, p-methylphenyl, p-methoxyphenyl, indole, p-cyanophenyl, p-trifluoromethylphenyl, p-trifluoromethoxyphenyl, p-nitrophenyl, or a naphthalene ring. In formula (IC), R3 is selected from hydrogen, o-fluorine, m-fluorine, p-fluorine, m-chloro, p-chloro, p-methyl, o-methoxy, m-methoxy, or p-methoxy. The galantamine analogue of this invention has superior inhibitory activity against cholinesterase compared to galantamine, and is expected to be used to treat cholinergic dysfunction-related diseases.
Owner:SHENYANG PHARMA UNIV
Anticholinergic compounds for use in treating neuromuscular disorders
The present invention relates to an anticholinergic compound such as Darifenicin for use in the treatment of a neuromuscular disorder (in particular amyotrophic lateral sclerosis or ALS) in a human subject, wherein the neuromuscular disorder is characterized by an impaired neuromuscular transmission and / or an denervation at the NMJ (neuromuscular junction) and the anticholinergic agent is administered after symptomatic onset.
Owner:UNIV DE MONTREAL
Use of choline in the preparation of a medicament for treating placental damage induced by flame retardant EHDPP
The application relates to the application of choline in the preparation of a medicine for treating flame retardant EHDPP-induced placental injury. The functions of the choline include that cholinergic can alleviate the vitality inhibition, migration inhibition and inflammatory reaction of cells caused by EHDPP, and improve the placental injury caused by EHDPP. The choline includes choline and derivatives thereof, and the derivatives include choline chloride, choline hydroxide, choline phosphate and the like. The application provides a medicine preparation containing choline based on the above functions, and the medicine preparation can be used for treating / alleviating EHDPP-induced placental injury. Choline is a common and relatively safe nutrient, is low in cost, and is easy to popularize. Through double verification of in-vitro and in-vivo experiments, it is found and proved for the first time that choline has a positive effect on reducing EHDPP-induced placental injury, and a novel and effective solution is provided for solving the placental health problems caused by EHDPP exposure.
Owner:HANGZHOU INST FOR ADVANCED STUDY UCAS +1
Method for constructing microwave radiation animal brain injury model based on medial septal nucleus-hippocampal CA3 cholinergic nerve loop regulation
The application discloses a method for constructing a microwave radiation animal brain injury model based on a medial septum-hippocampus CA3 cholinergic nerve loop regulation, comprising the following steps: setting electromagnetic radiation conditions, and performing electromagnetic radiation treatment on test animals; comparing whether a cholinergic nerve loop between the medial septum and the hippocampus CA3 is activated before and after the electromagnetic radiation treatment; and if the cholinergic nerve loop is activated, constructing an electromagnetic radiation animal brain injury model by using the electromagnetic radiation conditions. The application can accurately construct the electromagnetic radiation animal brain injury model, and increases the possibility of elucidating the molecular mechanism of the electromagnetic radiation brain injury effect and the research and development of prevention and treatment drugs.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES